Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Equivalents (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Cash & Equivalents for 8 consecutive years, with $230.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 2.58% year-over-year to $230.9 million, compared with a TTM value of $230.9 million through Dec 2025, down 2.58%, and an annual FY2025 reading of $230.9 million, down 2.58% over the prior year.
  • Cash & Equivalents was $230.9 million for Q4 2025 at Arcturus Therapeutics Holdings, up from $180.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $466.8 million in Q1 2021 and bottomed at $180.4 million in Q3 2025.
  • Average Cash & Equivalents over 5 years is $317.8 million, with a median of $315.8 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 684.99% in 2021, then plummeted 42.57% in 2022.
  • Year by year, Cash & Equivalents stood at $370.5 million in 2021, then increased by 5.77% to $391.9 million in 2022, then dropped by 25.49% to $292.0 million in 2023, then fell by 18.83% to $237.0 million in 2024, then dropped by 2.58% to $230.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for ARCT at $230.9 million in Q4 2025, $180.4 million in Q3 2025, and $237.0 million in Q4 2024.